[go: up one dir, main page]

ES2098261T3 - Formas modificadas de hormonas reproductoras. - Google Patents

Formas modificadas de hormonas reproductoras.

Info

Publication number
ES2098261T3
ES2098261T3 ES90905115T ES90905115T ES2098261T3 ES 2098261 T3 ES2098261 T3 ES 2098261T3 ES 90905115 T ES90905115 T ES 90905115T ES 90905115 T ES90905115 T ES 90905115T ES 2098261 T3 ES2098261 T3 ES 2098261T3
Authority
ES
Spain
Prior art keywords
modified forms
reproductive hormones
hormones
reproductive
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90905115T
Other languages
English (en)
Inventor
Irving Boime
Martin M Matzuk
Jeffrey L Keene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Application granted granted Critical
Publication of ES2098261T3 publication Critical patent/ES2098261T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Paper (AREA)

Abstract

ESTA INVENCION SUMINISTRA FORMAS NATIVAS RECOMBINANTES Y MUTANTES DE HORMONAS REPRODUCTIVAS HUMANAS, CON PAUTAS DE GLICOSILACION CARACTERISTICAS, QUE SON INFLUENCIABLES EN LA ACTIVIDAD METABOLICA DE LAS PROTEINAS. ESTA INVENCION TAMBIEN SUMINISTRA FORMAS MUTANTES RECOMBINADAS DE LA SUBUNIDAD ALFA HUMANA A FSH, LH, CG Y TSH, PARA OBTENER HORMONAS QUE TAMBIEN TIENEN PAUTAS DE GLICOSILACION UNICAS. TAMBIEN SE DAN MATERIALES RECOMBINADOS PARA LA PRODUCCION DE ESTAS SUBUNIDADES, CONJUNTA O SEPARADAMENTE, PARA OBTENER HORMONAS HETERODIMERICAS COMPLETAS DE PAUTAS Y ACTIVIDAD DE GLICOSILACION REGULADA. TAMBIEN SE DESVELAN LAS FORMAS MODIFICADAS DE LAS SUBUNIDADES BETA LH Y FSH, QUE AUMENTAN LA PROPORCION DE DIMERIZACION Y SECRECION DE LOS DIMEROS O CADENAS INDIVIDUALES.
ES90905115T 1989-02-21 1990-02-20 Formas modificadas de hormonas reproductoras. Expired - Lifetime ES2098261T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31364689A 1989-02-21 1989-02-21

Publications (1)

Publication Number Publication Date
ES2098261T3 true ES2098261T3 (es) 1997-05-01

Family

ID=23216537

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90905115T Expired - Lifetime ES2098261T3 (es) 1989-02-21 1990-02-20 Formas modificadas de hormonas reproductoras.

Country Status (12)

Country Link
US (5) US5177193A (es)
EP (1) EP0461200B1 (es)
JP (1) JP3045539B2 (es)
AT (1) ATE148171T1 (es)
AU (2) AU648020B2 (es)
CA (1) CA2053864C (es)
DE (2) DE122010000006I2 (es)
DK (1) DK0461200T3 (es)
ES (1) ES2098261T3 (es)
LU (1) LU91648I2 (es)
NL (1) NL300434I1 (es)
WO (1) WO1990009800A1 (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5240832A (en) * 1989-06-20 1993-08-31 Genzyme Corporation Heteropolymeric protein production methods
DE69231129D1 (de) * 1991-06-18 2000-07-06 Univ New Jersey Med Analoga von glykoproteinhormonen mit geänderter rezeptorbindungsspezifität und aktivität und verfahren zur darstellung und verwendung derselben
US6028177A (en) * 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5985611A (en) * 1992-04-30 1999-11-16 Washington University Recombinant production of gonadotropins in secretory cells
FI954978L (fi) * 1993-04-20 1995-11-15 Univ Washington Modifioidut proteiini- ja peptidilääkeaineet
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
US5643745A (en) * 1994-02-03 1997-07-01 University Of Hawaii Heterologous dimeric proteins produced in heterokaryons
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
GB9403600D0 (en) * 1994-02-24 1994-04-13 Univ Glasgow Three dimensional hormone structure
AU2603995A (en) * 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
MX9601320A (es) * 1994-08-12 1997-05-31 Univ Washington Formas de cadena unica de cuarteto de hormona de glicoproteina.
EP0725795B1 (en) * 1994-08-12 2004-01-14 Washington University Single-chain forms of the glycoprotein hormone quartet
RU2213099C2 (ru) * 1994-08-12 2003-09-27 Вашингтон Юниверсити Одноцепочечный белок, модулятор гормонов лютеинизирующего, фолликулостимулирующего, тиреостимулирующего и хорионического гонадотропина (варианты), молекула нуклеиновой кислоты (варианты), вектор (варианты), линия трансформированных клеток сно (варианты), способ продуцирования одноцепочечного белка (варианты)
US5733735A (en) * 1996-06-11 1998-03-31 Washington University Assay system to determine receptor antagonist target site
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US5883073A (en) * 1997-04-03 1999-03-16 Washington University Single-chain double-alpha peptide
AU758156B2 (en) * 1997-09-22 2003-03-13 University Of Maryland At Baltimore Mutants of thyroid stimulating hormone and methods based thereon
US6635256B1 (en) 1998-10-19 2003-10-21 Washington University Glycoprotein hormone compositions comprising two β subunits and methods of use thereof
US6103501A (en) * 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
EP1169053A1 (en) 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
PL207728B1 (pl) * 2000-02-22 2011-01-31 Serono Lab Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna
EP1257564B1 (en) * 2000-02-22 2008-08-27 Laboratoires Serono SA Process for purification of recombinant hcg having a specific bioactivity
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
JP2001333772A (ja) 2000-04-25 2001-12-04 Washington Univ 可変性の活性を有する単鎖稔性ホルモン
US20040005554A1 (en) * 2000-05-08 2004-01-08 Tayar Nabil El Novel glycoproteins and methods of use thereof
US6493964B1 (en) 2000-05-25 2002-12-17 Tousimis Research Corp. Supercritical point drying apparatus for semiconductor device manufacturing and bio-medical sample processing
ATE320449T1 (de) * 2000-12-11 2006-04-15 Cheil Jedang Corp Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
KR101229995B1 (ko) * 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US6987172B2 (en) 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CN1596304A (zh) * 2001-11-08 2005-03-16 威廉R·莫伊尔 蛋白质结节
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7173113B2 (en) * 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
WO2003094858A2 (en) * 2002-05-13 2003-11-20 Modigenetech Ltd. Ctp-extended erythropoietin
US20060177894A1 (en) * 2002-11-08 2006-08-10 Moyle William R Protein knobs
EP1610803B8 (en) 2003-03-04 2011-09-14 AspenBio Pharma, Inc. LH for use in maintaining one or more pregnancies by inducing accessory corpus luteum formation.
PT1673105E (pt) * 2003-07-25 2007-06-20 Serono Lab ''utilizaçao da hormona estimulante do folículo para a redução de aberrações cromossómicas em espermatozóides em indivíduos do sexo masculino''
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
CA2545160A1 (en) * 2003-11-06 2005-05-19 Compugen Ltd. Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
US20050220640A1 (en) * 2004-04-02 2005-10-06 Finkenbinder David B Fan motor assembly with noise suppression
WO2006015005A2 (en) * 2004-07-27 2006-02-09 Genzyme Corporation Use of thyrotropin for regeneration of bone
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
US20080039372A1 (en) * 2005-07-21 2008-02-14 The Trustees Of Columbia University In The City Of New York Human chorionic gonadotropin antagonists and methods to prevent ovarian hyperstimulation
PL1917276T3 (pl) * 2005-08-26 2018-08-31 Ares Trading S.A. Sposób wytwarzania glikozylowanego interferonu beta
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
US20100249381A1 (en) * 2007-10-22 2010-09-30 David Delvaille Method for Purifying FC-Fusion Proteins
CA2701221A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US9062299B2 (en) 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
PL2729161T3 (pl) 2011-07-08 2019-08-30 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
CN103930134B (zh) 2011-07-18 2016-12-21 阿茨生物股份有限公司 长效促黄体激素(lh)化合物
AU2013219935B2 (en) 2012-02-14 2016-02-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
HRP20190454T1 (hr) 2012-02-15 2019-05-03 Bioverativ Therapeutics Inc. Rekombinantni faktor viii proteini
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
MY172997A (en) 2012-11-20 2019-12-18 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
CN103509121B (zh) 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
PL3889173T3 (pl) 2013-02-15 2023-12-11 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
WO2014144795A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor viii polypeptide formulations
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
ES2811068T3 (es) 2013-10-21 2021-03-10 Opko Biologics Ltd Polipéptidos de acción prolongada y métodos para producir y administrar los mismos
CN103539860B (zh) * 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015148444A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Lyophilized factor ix formulations
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
KR102164352B1 (ko) 2014-12-10 2020-10-13 옵코 바이오로직스 리미티드 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
IL315314A (en) 2016-07-11 2024-10-01 Opko Biologics Ltd Long-acting coagulation factors and methods of producing same
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
WO2019211842A1 (en) 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same
MA52630A (fr) 2018-05-18 2021-05-26 Bioverativ Therapeutics Inc Procédés de traitement de l'hémophilie a
CN108676096B (zh) * 2018-05-22 2022-03-29 北京伟杰信生物科技有限公司 重组猪fsh-ctp融合蛋白及其制备方法与应用
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
TW202039855A (zh) 2018-12-06 2020-11-01 美商百歐維拉提夫治療公司 表現因子ｉｘ之慢病毒載體的用途
US11254530B2 (en) * 2019-03-26 2022-02-22 Toshiba Tec Kabushiki Kaisha Sheet aligning mechanism
BR112021022860A2 (pt) 2019-05-16 2022-01-18 Ceva Sante Animale Composições e métodos para aumentar o desempenho da reprodução em mamíferos não humanos com uso de hormônio luteinizante recombinante
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
ATE190461T1 (de) * 1983-11-02 2000-04-15 Applied Research Systems Produkte und methoden für die herstellung einer heterodimerer menschlicher lh mit einem met42 val55 alpha untereinheit
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4923805A (en) * 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
US4668476A (en) * 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4717670A (en) * 1984-06-08 1988-01-05 Integrated Genetics, Inc. Porcine beta FSH
NZ213759A (en) * 1984-10-19 1989-01-27 Genentech Inc Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
CA1239346A (en) * 1985-06-04 1988-07-19 Gursaran P. Talwar Birth control vaccine
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4804626A (en) * 1986-10-22 1989-02-14 The General Hospital Corporation Immunometric assay for the detection of human chorionic gonadotropin
US4780451B1 (en) * 1987-01-23 1995-04-04 Asua International Inc Composition and method for producing superovulation in cattle
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors

Also Published As

Publication number Publication date
EP0461200A1 (en) 1991-12-18
AU6581996A (en) 1997-01-16
US5712122A (en) 1998-01-27
AU648020B2 (en) 1994-04-14
CA2053864A1 (en) 1990-08-22
DK0461200T3 (da) 1997-03-10
AU670510B2 (en) 1996-07-18
EP0461200B1 (en) 1997-01-22
DE69029799D1 (de) 1997-03-06
DE122010000006I1 (de) 2010-05-06
EP0461200A4 (en) 1992-11-19
DE69029799T2 (de) 1997-05-28
AU5332790A (en) 1990-09-26
US5405945A (en) 1995-04-11
WO1990009800A1 (en) 1990-09-07
AU697899B2 (en) 1998-10-22
CA2053864C (en) 2001-11-20
US5177193A (en) 1993-01-05
JP3045539B2 (ja) 2000-05-29
ATE148171T1 (de) 1997-02-15
US5585345A (en) 1996-12-17
JPH04503606A (ja) 1992-07-02
NL300434I1 (nl) 2010-04-01
AU6747494A (en) 1994-09-29
LU91648I2 (fr) 2010-04-06
DE122010000006I2 (de) 2012-06-21
US6306654B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
ES2098261T3 (es) Formas modificadas de hormonas reproductoras.
ES2052829T3 (es) Aminoetiltetralinas substituidas asi como sus analogos heterociclicos.
LU90806I2 (fr) Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables
DE3888385D1 (de) Projektionsschirm mit hoher Auflösung und guter mechanischer Stabilität.
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
DE3579148D1 (de) Polypeptid und polypeptidzusammensetzung.
IL60697A0 (en) Homogeneous fibroblast interferon and its manufacture
DE69528531D1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
DE69529674D1 (de) Biologisch aktive ligande der eph familie
DE68900847D1 (de) Dispergiermittelzusammensetzung fuer zement.
DE68908138D1 (de) Polypeptide mit zellausdehnungs-aktivitaet.
DE68907941D1 (de) Polypeptide mit zellausdehnungs-aktivitaet.
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
PH19787A (en) Polypeptides processes their production,pharmaceutical compositions comprising said polypeptides and their use
FI841649L (fi) Biologiskt aktiva polypeptider.
DE69121970D1 (de) Flugzeugantenne mit Korrektur von Fehlern, verursacht durch die konische Form des Antennenstrahls und durch Flugzeugschräglage
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
ZA935441B (en) Biologically active porcine somatotropin polypeptides and methods of using the same.
ES2058386T3 (es) Nuevos medicamentos con contenido de compuestos de 1,2-ditiol-3-tion-5-oxido.
ES2065363T3 (es) Amidas de acido n-indoliletil-sulfonico substituidas con 2-halogeno, procedimiento para su fabricacion y su uso en medicamentos.
LV10952A (lv) Terapeitiski aktivi fluoraizvietoti benzimidazoli to iegusanas panemieni mineto terapeitiski aktivo fluoraizvietoto benzimidazolu pielietojums
DK527287D0 (da) Polypeptid med interleukin-2-aktiviteter
IT8420759A0 (it) Composizione ad attivita'farmaceutica perfezionata e sua utilizzazione per usi veterinari.
DK0484331T3 (da) Enkeltkrystaller af -g(b)-phenylpropiophenoner
MX9203582A (es) Peptidos y composiciones farmaceuticas con actividad agonista y antagonista de la hormona de glicoproteina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 461200

Country of ref document: ES